key: cord-0995273-3xcr39cp authors: Rodler, Severin; Apfelbeck, Maria; Stief, Christian; Heinemann, Volker; Casuscelli, Jozefina title: Lessons from the COVID-19 pandemic – will virtual patient management reshape uro-oncology in Germany? date: 2020-04-20 journal: Eur J Cancer DOI: 10.1016/j.ejca.2020.04.003 sha: 842c7819fe822a425a917dc3406d4f9a92c6849d doc_id: 995273 cord_uid: 3xcr39cp Abstract The Coronavirus disease (COVID-19) pandemic is challenging for physicians treating patients with genitourinary cancers as those are considered at high risk for severe events. The uro-oncology outpatient clinic at our academic institution was affected early by the outbreak due to the widespread infection of health care personnel. Subsequently, we developed a strategy to ensure patient’s safety by efforts focused on strict quarantine observation, reduction of clinic visits and implementation of virtual patient management into the workflow. Further, we analyze susceptibility to COVID-19 and its effects on uro-oncological patients treated with anti-tumoral agents. The goal is to warrant high quality cancer care, despite being an academic center on the front-line of Germany’s response to COVID-19. The current Coronavirus disease (COVID-19) crisis seems to heavily affect patients with metastatic cancers: preliminary data shows that cancer patients might be more exposed to the risk of infection due to the high frequency of outpatient visits [1] and develop more severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections [2] . Here we present a best practice example on management of patients with metastatic genitourinary cancers during the current COVID-19 crisis. Our academic institution has been affected early during this pandemic which urged us to adapt and implement changes in our standard treatment and follow-up procedures. We further aim to scrutinize the still unclear susceptibility of cancer patients [3] with several comorbidities to the novel coronavirus and the long-term effects of the pandemic outbreak in the uro-oncology population. Patients undergoing systemic therapy for genitourinary cancers are prospectively included into a database at the university hospital of Munich (LMU). Chronic underlying diseases, side effects of therapies, response to therapy and survival data is prospectively collected. Prior to initiation of the study the local ethics authorities (Ethikkommission der Ludwig-Maximilian-Universität München) revised the project design and granted approval for the study (Reference number 19-942). For diagnosis of SARS-CoV-2 infections deep nasal swabs were taken 4 days after the contact with SARS-CoV-2 positive individuals. A second swab was performed 4 days after the initial test. Testing for SARS-CoV-2 was performed either at the Department of Virology of LMU Munich or at the Institute for Infectious Diseases and Tropical Medicine of LMU Munich. PCR was run for SARS-CoV-2-RNA N-Gene 1. All patients with exposure to SARS-CoV-2 positive healthcare staff have been followed up daily for symptoms via phone or e-mail and were asked to write a symptom diary. They were advised to contact the primary care physician in case of mild symptoms and low-grade fever and go to the emergency room in case of severe symptoms and high fever. Asymptomatic patients were asked to contact the local health authority to perform a SARS-CoV-2 RNA PCR test 4 days after contact with the infected staff. Primary care physicians were asked to perform blood work at the patient's home when necessary for the treatment regimen. 120 Patients with metastatic malignancies of the bladder (n=48), kidney (n=32) or prostate (n=40) are currently under systemic therapy on our outpatient uro-oncology clinic (Table 1) . Median age of all patients is 70 years (Range 33 to 90). Patients receive chemotherapy (n=30), immunotherapy (n=56), tyrosine kinase inhibitors following immunotherapy (n=5), secondary androgen deprivation following upfront chemotherapy (n=23) and Bacillus Calmette-Guérin (BCG) (n=2). 26 patients visited the specialized outpatient uro-oncology clinic during the outbreak of COVID-19 either for therapy or consultation. 23 were directly exposed to healthcare personnel tested positive for SARS-CoV-2 and one patient was infected and was tested positive. In Munich, the first confirmed COVID-19 case was reported on February 1 st . On February 27 th the Ludwig-Maximilian-University Hospital implemented guidelines to face the upcoming COVID-19 situation. In the uro-oncology unit we introduced surgery masks for patients and physicians on March 11 th [4] . Despite all safety precautions, a COVID-19 outbreak occurred amongst the healthcare staff of the multidisciplinary outpatient oncology clinic, after a nurse developed symptoms and was tested positive to the novel coronavirus on March 19 th . In the following, all healthcare personnel in direct contact with the symptomatic nurse were screened for the SARS-CoV-2. One of the three urologists from the uro-oncology team was tested positive, as well as the entire nursing team and 3 physicians from the medical oncology department. 24 hours after the disclosure of the test results of the personnel the entire unit of the multidisciplinary outpatient oncology clinic was shut down. Upon negative testing, only one urologist was dedicated to the care of all uro-oncological patients [5] on a bi-weekly rotation in order to minimize patient's contact to staff. The physician observes frequent hand sanitation and maintains adequate distance to patients, while wearing a surgical mask. All uro-oncological patients are now treated in the urology outpatient clinic, currently used only for ambulant emergency procedures. 23 out of 26 uro-oncology patients were exposed to infected healthcare personnel in the outpatient oncology clinic (Figure 1 ): all were called and advised to undergo a strict quarantine according to national guidelines [6] (for further follow-up see Methods). As of April 1 st none of the patients developed symptoms and due to initial shortage in testing resources, only 5 patients underwent a swab to detect the SARS-CoV-2. 4-6 days following the exposure all initial tests were negative and 1 patient tested positive in the follow-on test. For all our uro-oncology patients not directly affected by the outbreak, we increase the alertness and follow infection protection measures while continuing safe and effective antitumoral treatment. We aim to decentralize patient care from the academic center to the primary and secondary care providers, but keep the oversight over the treatment. Here, we leverage a network of cooperating physicians, radiologists, urologists and oncologists to reduce the risk of contact with infected patients in our hospital. Diagnostic blood tests and imaging for treatment followup and staging are preferably outsourced to private practices. Upon receipt of the reports, the uro-oncology team calls and counsels the patients. Symptom checking is implemented by phone calls and we are working on a specific patient reported outcome app with COVID-19 modules [7] . Monitoring and management of side effects from antitumoral therapy [8] are currently offered virtually and clinic consultation are performed by phone calls and intensified e-mail contact. Documentation and patient data are transferred according to the current data protection laws [9] . Reimbursement for telehealth offers has been implemented for this exceptional situation. Enrollment in clinical trials is paused. To save capacities in the healthcare system and reduce the risk of infection, subjects in ongoing trials are seen solely for the administration of medication. Study follow-up is maintained virtually and testing is decentralized to private practices. Multidisciplinary tumor boards for treatment decisions are currently being transformed to teleor video conferences. Start of palliative systemic treatments, like chemotherapies, is advised, but if options with lower risk of immunosuppression are equivalent, they are prioritized (e.g. secondary hormonal therapy against docetaxel [10] ). We reduce the number of visits per patient to an absolute minimum and prohibit patient's companions during the visits. Before planned visits, patients are contacted to preclude COVID-19 symptoms. Upon hospital entry, patients are equipped with a surgical face mask and are directly guided towards a single room to avoid any contact with other patients or irrelevant healthcare personnel, but the treating physician. Where feasible and safe immunotherapy regimens are changed towards higher doses with prolonged interval [11] . Patients on chemotherapy are referred to private practices with lower patient throughput. All patients with chemotherapies at high-risk of febrile neutropenia are treated with prophylactic growth hormones and or are subject to chemotherapy dosage reductions. Based on our prospectively maintained institutional database we study characteristics of patients in direct contact with COVID-19 positive individuals (Table 1) . Data enrichment by merging information from institutions with similar experiences will promote evidence regarding the susceptibility of uro-oncological patients towards COVID-19. The early precautions adapted ensured a low infection rate in our vulnerable patient population despite the widespread outbreak among the health care staff. Close monitoring of exposed patients and strategies to confine the infection risk for all our uro-oncological patients potentially lead to lower spread of COVID-19 without compromising cancer treatment. As data on long-term follow up is missing to date, we aim to prospectively collect data to assess the effectiveness of the actions taken and the treatment regimen modifications adapted. With continuation of the pandemic, our approach should be implemented and extended to all oncologic patients primarily treated at academic centers directly facing the challenges of the COVID-19 pandemic. From our experience, we learn that virtual management and visit frequency reductions are feasible and will likely impact the future treatment approach of genitourinary cancers patients after the crisis. Control and Prevention: Basic Infection Control and Prevention Plan for Outpatient Oncology Settings Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Risk of COVID-19 for cancer patients. The Lancet Oncology Universal Masking in Hospitals in the Covid-19 Era ESMO: SPLITTING HEALTHCARE TEAMS MAY HELP TO REDUCE DISRUPTION IN PATIENT CARE Kontaktpersonennachverfolgung bei respiratorischen Erkrankungen durch das Coronavirus SARS-CoV-2 CANKADO COVID-19 CAREGIVER COCKPIT Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Regulation (EU) 2016/679 of the European Parliament on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China Patients with visit during outbreak Total number of patients treated in our uro-oncologic clinic: 120 Further treatment at LMU with changed treatment regimen 2 : Further treatment at LMU (visits only for therapy Patients tested negative for COVID-19: 5 Patients without testing Direct contact with COVID-19+ staff: 23 No direct contact with COVID-19+ staff: 3 No visit during outbreak Chemotherapy: 2 Immunotherapy: 11 BCG (Clinical trial): 2 Chemotherapy: 8 Immunotherapy Chemotherapy: 20 Immunotherapy: 3 Virtual surveillance and therapy decisions: Chemotherapy: 0 Immunotherapy 3 : 13 Androgen deprivation therapy: 23 Tyrosine kinase inhibitor: 5 Other The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Patients on systemic therapy who had direct contact with SARS-CoV-2 positive healthcare personnel were followed up for symptoms. As testing capacities were insufficient at this time of the pandemic, only 6 patients received a COVID-19 testing as described. • Covid-19 pandemic requires quick and effective changes in the management of patients with genitourinary cancers • Virtual patient management, reevaluation of treatment regimens and transferring patients into primary and secondary centers are the strategies to adapt.• Implementation of telehealth into workflows might impact cancer care after the pandemic in Germany ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: